drugset / Trial / NCT02705482
A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate MEDI0562 in combination with immune therapeutic agents in adult subjects with select advanced solid tumors.
Timeline
- Start
- 2016-03-30
- Primary completion
- 2019-08-07
- Completion
- 2019-08-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | TAVOLIMAB | Monoclonal antibody | 2.25 mg | Intravenous |
| Subject | TAVOLIMAB | Monoclonal antibody | 7.5 mg | Intravenous |
| Subject | TAVOLIMAB | Monoclonal antibody | 22.5 mg | Intravenous |
| Subject | Tremelimumab | Monoclonal antibody | 75 mg | Intravenous |
| Subject | Tremelimumab | Monoclonal antibody | 225 mg | Intravenous |